Zéna Wimana

Service(s) : Médecine nucléaire

zena.wimana [at] bordet.be

Publications

Understanding the Radiobiological Mechanisms Induced by (177)Lu-DOTATATE in Comparison to External Beam Radiation Therapy.

Auteurs : Delbart W, Karabet J, Marin G, Penninckx S, Derrien J, Ghanem GE, Flamen P, Wimana Z
Année : 2022
Journal : Int J Mol Sci

Investigating intrinsic radiosensitivity biomarkers to peptide receptor radionuclide therapy with [<sup>177</sup>Lu]Lu-DOTATATE in a panel of cancer cell lines.

Auteurs : Delbart W, Ghanem G, Karfis I, Flamen P, Wimana Z
Année : 2021
Journal : Nucl Med Biol

Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option.

Auteurs : Mileva M, Wimana Z, Flamen P, Karfis I
Année : 2021
Journal : World J Nucl Med

Downregulation of the FTO m<sup>6</sup>A RNA demethylase promotes EMT-mediated progression of epithelial tumors and sensitivity to Wnt inhibitors.

Auteurs : Jeschke J, Collignon E, Al Wardi C, Krayem M, Bizet M, Jia Y, Garaud S, Wimana Z, Calonne E, Hassabi B, Morandini R, Deplus R, Putmans P, Dube G, Singh NK, Koch A, Shostak K, Rizzotto L, Ross RL, Desmedt C, Bareche Y, Rothé F, Lehmann-Che J, Duterque-Coquillaud M, Leroy X, Menschaert G, Teixeira L, Guo M, Limbach PA, Close P, Chariot A, Leucci E, Ghanem G, Yuan BF, Willard-Gallo K, Sotiriou C, Marine JC, Fuks F
Année : 2021
Journal : Nat Cancer

68Ga-PSMA PET/CT-based metastasis-directed radiotherapy for oligometastatic prostate cancer recurrence after radical prostatectomy.

Auteurs : Artigas C, Flamen P, Charlier F, Levillain H, Wimana Z, Diamand R, Albisinni S, Gil T, Velthoven Rv, Peltier A, Van Gestel D, Roumeguere T, Otte FX
Année : 2019
Journal : World J Urol

Plus de publications »

Zéna Wimana

Suivez-nous!

Le nouvel Institut Jules Bordet.

Languages

Contact